Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2019 May 31;7(7):1202–1213. doi: 10.1158/2326-6066.CIR-18-0498

Figure 2. ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming activity.

Figure 2

(A) The total trimming activity for all 20 X-SHL8 substrates for each allotype combination were combined and grouped into CD8/TIL status. Overall trimming for each CD8/TIL group is represented as area under curve (AUC). (B) Table showing both the individual AUC for allotype pairs in each CD8/TIL group as well as the mean for each group. (C) Specificity of ERAP1 trimming activity from those found exclusively in CD8/TILhigh, CD8/TILmoderate or CD8/TILlow tumors towards X-SHL8 amino acids grouped based on physicochemical properties; basic, acidic, polar uncharged, aliphatic, aromatic and special. Data from (A-C) pooled from four independent experimental repeats ±SEM (***p = <0.001; **p = <0.01; *p = <0.05).